Patient Resources & Materials
Patient Materials
Medication Guide
Please read the patient Medication Guide before each RITUXAN treatment.
Download PDF
Living With Non-Hodgkin's Lymphoma (NHL): A Guide for Non-Hodgkin's Lymphoma Patients
This resource offers suggestions for dealing with emotions you may feel when coping with NHL. It offers tips to help you feel more in control and lists questions you may want to ask your healthcare provider.
Download PDF
Your Questions about Non-Hodgkin’s Lymphoma (NHL)
This guide will help you discuss NHL with your healthcare provider. It offers a number of sample questions to help you understand your diagnosis and treatment, as well as manage your side effects.
Download PDF
Web sites
For a list of helpful Web sites, click here.
Organizations
Genentech, Inc. and Biogen Idec, Inc. are neither affiliated with nor endorse any of the following organizations. The information provided by Genentech, Biogen Idec, or these organizations is meant for informational purposes only and is not meant to replace your physician's medical advice. Most of the contact phone numbers are toll free. Many of these organizations can refer you to a local chapter for more information.
The Leukemia & Lymphoma Society (LLS)
1311 Mamaroneck Avenue
White Plains, NY 10605
Phone: (914) 949-5213
Toll free: (800) 955-4572
Lymphoma Research Foundation
8800 Venice Boulevard, Suite 207
Los Angeles, CA 90034
Phone: (310) 204-7040
Toll free: (800) 500-9976
Booklets
Understanding Non-Hodgkin's Lymphoma: A Guide for Patients. Lymphoma Research Foundation. 2004. To order a copy, please call (800) 500-9976.
The Lymphomas: A Guide for Patients and Their Families. Hodgkin and Non-Hodgkin Lymphoma Information. The Leukemia & Lymphoma Society. 2005. To order a copy, please call (800) 955-4572.
What You Need To Know About Non-Hodgkin's Lymphoma. National Cancer Institute. 2005. To order a copy, please call (800) 4-CANCER.
INDICATIONS
RITUXAN® (rituximab) is indicated for the treatment of patients with:
- Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
- Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
- Non-progressing (including stable disease), low-grade, CD20-positive B-cell NHL, as a single agent, after first-line CVP chemotherapy
- Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
IMPORTANT SAFETY INFORMATION
RITUXAN can cause serious side effects, some of which can be life-threatening, including: Progressive Multifocal Leukoencephalopathy (PML), infusion reactions, Tumor Lysis Syndrome (TLS), and severe skin reactions. Other serious and life-threatening side effects with RITUXAN include: hepatitis B virus reactivation, heart problems, infections, and stomach and bowel problems. Common side effects during RITUXAN infusions include: fever, headache, chills and shakes, nausea, itching, hives, cough, sneezing, and throat irritation or tightness.
Tell your doctor about any side effects that bother you or that do not go away. These are not all of the possible side effects with RITUXAN. Ask your doctor for more information.
Please read the Medication Guide in HTML or PDF versions for more information.
